Drag

Glenmark Pharmaceuticals Limited

Healthcare GLENMARK

1955.60INR
35.20 ( 1.83%)

Last update at

Day Range

1947.602006.60
LowHigh

52 Week Range

1272.38 2279.21
LowHigh

Fundamentals

  • Previous Close 1920.40
  • Market Cap 586921.21M
  • Volume494,776
  • P/E Ratio 58.24
  • EBITDA 39175.21M
  • Revenue TTM 159966.22M
  • Revenue Per Share TTM 566.88
  • Gross Profit TTM 113716.84M
  • Diluted EPS TTM 35.71

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Past Performance

Status Stocks Entry Price Entry Date Exit Date Duration Duration Type Sector *Return(%)
CLOSED GLENMARK ₹ 1435.40 21/05/25 5/06/25 14 Days Mid Term Healthcare 8.12%

Financials

Income Statement

Total Revenue
Net Income

Balance Sheet

Total Assets
Total Liabilities

Change in Cash

Breakdown 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Type yearly yearly yearly yearly yearly
Income before tax 13992.09M 364.95M 8684.51M 14412.46M 13824.75M
Net income 10470.97M -15016.68M 2972.45M 9417.11M 9700.88M
Total Revenue 133632.94M 126453.83M 127254.33M 121741.98M 108060.26M
Gross Profit 88382.78M 80664.79M 81884.79M 77144.91M 70622.19M
Breakdown 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Type yearly yearly yearly yearly yearly
Date 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Total assets 160495.54M 143586.24M 193716.76M 170832.88M 156035.77M
Intangible assets 13900.33M 12672.06M 23606.83M 22253.79M 22769.38M
Other current assets 11573.14M 13925.68M 11536.17M 2770.97M 12275.50M
Deferred long term liab - - - - -
Non current assets other - - - - -
Breakdown 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Type yearly yearly yearly yearly yearly
Date 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Change in Cash 174.37M 2152.44M 325.00M 2724.31M 278.20M
Operating Cash -8275.95M -2654.44M 6253.92M 11086.52M 11312.13M
Free Cash Flow -15771.64M -11638.22M 176.29M 3185.35M 3564.55M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change Price Market Cap (M) P/E Ratio
GLENMARK
Glenmark Pharmaceuticals Limited 		35.20 1.83% 1955.60 586921.21 58.24
SUNPHARMA
Sun Pharmaceutical Industries Limited 		74.80 4.59% 1702.70 4224508.76 40.32
DIVISLAB
Divi's Laboratories Limited 		260.50 4.38% 6213.00 1752225.28 70.47
TORNTPHARM
Torrent Pharmaceuticals Limited 		52.30 1.31% 4039.50 1362716.66 63.48
CIPLA
Cipla Limited 		9.90 0.75% 1321.50 1183505.97 21.74

Profile

Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and sells generics, specialty medicines, and over the counter (OTC) pharmaceutical products in India, North America, Europe, and internationally. The company provides branded, OTC, and generic formulations in the therapeutic areas of dermatology, respiratory, oncology, immunology, pain management, hypertension, central nervous system, cardiology, diabetes, contraceptives, gynecology, gastroenterology, and anti-infective in the dosage forms of complex injectables and biologics, oral solids, liquids, topical products, and respiratory-metered dose inhaler, dry powder inhaler, and nasal sprays. Its product pipeline includes ISB 2001, a CD38 x BCMA x CD3 TREAT trispecific T cell engager, which is in Phase 1 clinical trial for indication of relapsed/refractory multiple myeloma; ISB 2301, a NK cell engager that is in preclinical trial for solid tumors; and GRC 65327, a Cbl-b inhibitor small molecule for solid tumors. The company's pipeline also comprises ISB 880, an IL-1RAP antagonist monoclonal antibody, which is in Phase 1 clinical trial for the treatment of hidradenitis suppurativa; and ISB 830-X8, a telazorlimab OX40 antagonist antibody that is in Phase 2 clinical trial for the treatment of atopic dermatitis. In addition, the company offers Ryaltris nasal spray for the treatment of seasonal allergic rhinitis. The company was incorporated in 1977 and is based in Mumbai, India.

Glenmark Pharmaceuticals Limited

Glenmark House, Mumbai, India, 400099

Key Executives

Name Title Year Born
Mr. Glenn Mario Saldanha Chairman, MD & CEO 1970
Mr. V. S. Mani Global CFO & Exec. Director 1965
Ms. Cherylann Maria Pinto Exec. Director of Corp. Services & Exec. Director 1967
Mr. Alind Sharma Pres & Global Chief HR Officer 1971
Mr. Kaizad Adi Hazari Pres and Global Head of Legal, Compliance, IP & Corp. Affairs 1970
Mr. Ulhas R. Dhuppad Pres & Head of Global Pharmaceutical Devel. 1967
Mr. Sriram Venkatasubramanian Pres & Head of Global Operations and Supply Chain NA
Dr. Nikhil Amin Pres of Innovative Medicines Group & Chief Scientific Officer NA
Mr. Ravi Agrawal Investor Relations Officer NA
Mr. Harish Vinayak Kuber Company Sec. & Compliance Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data ("EODHD") on an 'as is' basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.